Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The world’s first NHS trial for a universal flu vaccine has recruited its first round of participants, with over 862 people signing up to take part since the trial launched in October 2017.

Led by Oxford University, the trial investigates whether giving the new vaccine at the same time as the existing vaccine offers stronger protection against flu in over 65-year olds. Current vaccines are only effective in 30–40% of over 65s, as the immune system weakens with age. Researchers believe the vaccine could have a major impact on the worldwide fight against the virus, which affects about a billion people worldwide a year with 250,000 to 500,000 annual deaths.

The vaccine was first developed by Oxford University’s Jenner Institute with Vaccitech, a spin-out company from the institute now continuing clinical development.

Find out more (Nuffield Department of Primary Care Health Sciences website)

Similar stories

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.

Three NHSBT research units launch at University of Oxford

The NIHR has awarded three new Blood and Transplant Research Units (BTRUs) to the University of Oxford.

Fourth COVID-19 vaccine dose provides stronger immunity boost than third dose, shows UK study

COVID-19 vaccines given as fourth doses in the UK offer excellent boosting immunity protection, according to the latest results from a nationwide NIHR-supported study.

COVID-19’s high blood clot risk

A recent study of patient health records found that around 1 in 100 people with COVID-19 had a venal or arterial thrombosis, with rates higher still among males, and particularly for those hospitalised.

Medical Sciences Division receives REF 2021 results

Today the UK Funding Bodies have published the outcomes of the recent national research assessment exercise, the Research Excellence Framework (REF) 2021. REF is the UK-wide assessment of research in universities, and provides an expert evaluation of the quality of the research outputs, impact and environment at subject level in each university.